BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Notice of Ablynx's Annual and Extraordinary General Meeting of Shareholders


3/26/2013 10:07:27 AM

GHENT, BELGIUM--(Marketwire - March 26, 2013) - Ablynx (EURONEXT BRUSSELS: ABLX) today announced that its 2013 Annual and Extraordinary General meeting (AGM) will be held on Thursday, 25 April 2013 at 11:00h CET at its headquarters at Technologiepark 21, 9052 Ghent.

The convocation and proxy statement, agenda, and annual accounts 2012 will be directly and permanently available on the Company's website at http://www.ablynx.com/en/investors/shareholder-information/shareholders-meeting/ from 26 March 2013.

The most important resolutions included in the agenda relate to the annual accounts 2012, the renewal of the authorised capital and the composition of the Board of Directors including the resignation of two non-executive Directors: Dr Roger Perlmutter who, to avoid conflicts of interest, is resigning from the Ablynx Board following his recent appointment at Merck & Co. as Executive Vice President and President of Merck Research Laboratories, and Geert Cauwenbergh who after five years will retire from the Ablynx Board.

About Ablynx
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 programmes in the pipeline and five Nanobodies at clinical development stage. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies including Boehringer Ingelheim, Merck Serono, Novartis and Merck & Co. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

press release in pdf: http://hugin.info/137912/R/1688051/553673.pdf


For more information, please contact
Ablynx:
Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com
Follow us on Twitter @AblynxABLX

M:Communications:
Mary-Jane Elliott, Amber Bielecka, Claire Dickinson
t: +44 207 920 2330
e: ablynx@mcomgroup.com



Read at BioSpace.com

Ablynx
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES